



IFW 16XX

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 015280-290110US
Client Ref. No.: E-171-1996/0-US-03
Customer No.: 45115

On 5-30-06

TOWNSEND and TOWNSEND and CREW LLP

By: Linda Shaffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KLIMPEL *et al.*

Application No.: 09/853,530

Filed: May 9, 2001

For: TARGETING ANTIGENS TO THE
MHC CLASS I PROCESSING
PATHWAY WITH AN ANTHRAX
TOXIN FUSION PROTEIN

Confirmation No. 7146

Examiner: Schwadron, Ronald B.

Technology Center/Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825 INCLUDING
STATEMENT UNDER 37 § C.F.R.
1.821(e)

AND

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed April 27, 2006, Applicants submit that the computer-readable form in the instant application is identical with the Substitute Sequence Listing filed in Application No. 08/937,276, hand-delivered on December 17, 2001. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in

Appl. No. 09/853,530
Amdt. dated May 22, 2006
Reply to Office Communication of April 27, 2006

PATENT

Application No. 08/937,276 as the computer-readable form for the instant application. The information in the paper copy of the Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.